Who are Prophylaxis with valganciclovir plus everolimus's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/prophylaxis-with-valganciclovir-plus-everolimus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Prophylaxis with valganciclovir plus everolimus — Competitive Intelligence Brief

Prophylaxis with valganciclovir plus everolimus (Prophylaxis with valganciclovir plus everolimus) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral, immunosuppressant. Area: Oncology, Infectious Diseases.

phase 3 Antiviral, immunosuppressant DNA polymerase, mTOR Oncology, Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Prophylaxis with valganciclovir plus everolimus (Prophylaxis with valganciclovir plus everolimus) — University of Bologna. Valganciclovir is an antiviral medication that inhibits viral DNA synthesis, while everolimus is an immunosuppressant that inhibits mTOR signaling.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prophylaxis with valganciclovir plus everolimus TARGET	Prophylaxis with valganciclovir plus everolimus	University of Bologna	phase 3	Antiviral, immunosuppressant	DNA polymerase, mTOR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral, immunosuppressant class)

University of Bologna · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prophylaxis with valganciclovir plus everolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/prophylaxis-with-valganciclovir-plus-everolimus. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab